I-Mab News

I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline

TipRanksApr 12 18:08

Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.

Zhitong FinanceApr 12 18:10

I-MAB Analyst Ratings

BenzingaApr 12 18:03

Needham Reiterates Buy on I-MAB, Maintains $6 Price Target

BenzingaApr 12 18:04

I-MAB Analyst Ratings

BenzingaMar 18 18:40

Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)

TipRanksMar 18 18:20

I-MAB Analyst Ratings

BenzingaMar 15 21:27

Needham Maintains Buy on I-MAB, Lowers Price Target to $6

BenzingaMar 15 21:28

I-MAB Buy Rating: Strategic Pivot to U.S. Market and Promising Pipeline

TipRanksFeb 12 21:18

I-MAB Analyst Ratings

BenzingaFeb 9 04:10

Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)

TipRanksFeb 9 04:10

Needham Maintains Buy on I-MAB, Lowers Price Target to $23

BenzingaSep 25, 2023 17:57

I-MAB Analyst Ratings

BenzingaSep 25, 2023 17:55

Cantor Fitzgerald Reiterates Overweight on I-MAB, Maintains $25 Price Target

BenzingaSep 5, 2023 21:59

I-MAB Analyst Ratings

BenzingaSep 5, 2023 21:58

Cantor Fitzgerald Reiterates Overweight on I-MAB, Maintains $25 Price Target

BenzingaAug 18, 2023 22:44

I-MAB Analyst Ratings

BenzingaAug 18, 2023 22:43

HC Wainwright & Co. Maintains Buy on I-MAB, Lowers Price Target to $18

BenzingaAug 18, 2023 20:44

I-MAB (IMAB) Gets a Buy From H.C. Wainwright

TipRanksAug 18, 2023 20:05

Needham Reiterates Buy on I-MAB, Maintains $24 Price Target

BenzingaAug 18, 2023 16:17